Q1 FY2022 (April 1 to June 30, 2022) Conference Call

Sumitomo Pharma Co., Ltd.



July 29, 2022

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties.

Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.

Myovant Sciences Ltd. ("Myovant") is listed on the New York Stock Exchange, and the Group holds approximately 52% of the outstanding shares of Myovant. ORGOVYX[®] (relugolix), MYFEMBREE[®]/RYEQO[®] (relugolix combination tablet) are owned by Myovant. This material contains information about Myovant, which is based on information disclosed by Myovant. For more information on Myovant, please visit https://www.myovant.com.





Financial Results for Q1 FY2022

Sumitomo Pharma

Financial Results for Q1 FY2022

Financial Results for Q1 FY2022 (Core Basis)

					,	Billic	ons of yen
	Q1YTD	Q1YTD		Change		FY20)22
	FY2021 Results	FY2022 Results	Value	FX impact	%	May 13 forecasts	%
Revenue	131.2	159.9	28.7	16.4	21.9	550.0	29.1
Cost of sales	38.5	46.1	7.6	4.0	19.7	164.5	28.0
Gross profit	92.7	113.8	21.1	12.4	22.8	385.5	29.5
SG&A expenses	62.0	76.0	14.1	9.2	22.7	283.5	26.8
R&D expenses	22.4	24.4	2.0	2.9	8.9	93.0	26.3
Other operating income/expenses	0.2	0.0	(0.2)	_	_	21.0	_
Core operating profit	8.5	13.4	4.9	0.3	57.2	30.0	44.6
Changes in fair value of contingent consideration (negative number indicates loss)	(0.1)	(0.1)	0.0			(0.5)	
Other non-recurring items (negative number indicates loss)	(0.1)	1.3	1.4			(5.5)	
Operating profit	8.3	14.6	6.3		75.9	24.0	60.9
Finance income/costs	(0.3)	32.0	32.3				
Profit before taxes	8.0	46.6	38.7		485.8		
Income tax expenses	7.2	18.5	11.4				
Net profit	0.8	28.1	27.3		_		
Net profit attributable to owners of the parent	4.8	31.1	26.3		547.8	22.0	141.4

The forecasts are not revised

(Ref.) Earnings related to Sumitovant Billions of yen					
	Q1 FY21	Q1 FY22			
Revenue	5.8	20.7			
SG&A expenses *	19.9	29.8			
R&D expenses	5.9	7.1			
Core operating profit	(20.7)	(20.8)			
Operating profit	(20.7)	(20.8)			
Net profit	(21.0)	(23.8)			
Net profit attributable to owners of the parent	(17.0)	(20.7)			

The figures include intra-group transaction

* Include amortization of patent rights

Average rates:

Q1FY2021 Results : 1US\$ = ¥109.5, 1RMB = ¥17.0 Q1FY2022 Results : 1US\$ = ¥129.7, 1RMB = ¥19.6 FY2022 forecasts : 1US\$ = ¥125.0, 1RMB = ¥19.5

Period end rates:

As of the end of March 2022 : 1US\$ = ¥122.4, 1RMB = ¥19.3 As of the end of June 2022 : 1US\$ = ¥136.6, 1RMB = ¥20.4

© Sumitomo Pharma Co., Ltd. All Rights Reserved. 3

Sumitomo Pharma

Financial Results for Q1 FY2022 Revenue of Major Products in Japan

	Q1 YTD	Q1 YTD	Cha	nge	FY20)22
	FY2021 Results	FY2022 Results	Value	%	May 13 forecasts	%
Equa [®] /EquMet [®]	9.8	8.8	∆1.0	∆10.4	34.9	25.2
Trulicity _® *	8.8	8.6	∆0.2	∆2.2	31.0	27.8
TRERIEF®	4.3	4.4	0.1	2.7	17.3	25.6
LATUDA [®]	1.4	2.3	0.9	65.5	9.9	23.2
METGLUCO [®]	2.1	2.0	∆0.1	∆5.2	7.8	25.5
LONASEN [®] Tape	0.5	0.7	0.2	41.6	2.7	24.4
TWYMEEG®	_	0.1	0.1	_	1.5	6.9
AG products	2.4	2.3	∆0.1	∆4.4	9.7	23.9
Others	9.3	4.5	∆4.9	∆52.1	15.2	29.4
合計	38.7	33.7	∆5.0	∆12.9	130.0	25.9

Note: Sales of each product are shown by invoice price (* Trulicity_® is shown by NHI price)

Billions of yen

- Progress is almost as forecasted in the segment total
- LATUDA[®] showing steady growth
- Prescription days limit of TWYMEEG[®] will be lifted in September 2022
- Sale of REPREGAL[®] included "Others" decreased (Q1 YTD FY2021: ¥3.5B)
- NHI price revision affected (¥3.2B) on Japan segment total

Financial Results for Q1 FY2022

Revenue of Major Products in North America & China

	Q1 YTD FY2021 Resuts	Q1 YTD FY2022 Results	Change	Q1 YTD FY2021 Resuts	Q1 YTD FY2022 Results	Value	Change FX impact	%	May 13 f	FY2022	Yen-basis %	-	North America segment Revenue increased due to the												
North America		Million \$			Billi	ions of yen			Million \$	Billions of yen			impact of fluctuations in FX rates												
LATUDA®	469	482	13	51.4	62.5	11.1	9.7	21.7	1,726	215.8	29.0		and products of Sumitovant Sale of LATUDA [®] is in line with												
APTIOM®	63	65	2	6.9	8.4	1.5	1.3	21.3	255	31.8	26.4		forecasts												
RETHYMIC®	—	5	5	—	0.7	0.7	0.1		48	6.0	11.8	-													
BROVANA®	51	14	∆37	5.6	1.8	∆3.8	0.3	△68.6	26	3.2	54.7	_													
KYNMOBI [®]	2	0	_∆2	0.2	0.0	∆0.3	0.0	△110.9	18	2.3	∆1.1	•	BROVANA [®] decreased due to loss of exclusivity in June 2021												
ORGOVYX [®]	11	36	25	1.2	4.7	3.5	0.7	293.5					······································												
MYFEMBREE®	1	4	3	0.1	0.5	0.4	0.1	339.8	601	75.2	29.0														
GEMTESA®	7	34	27	0.8	4.4	3.6	0.7	454.4			001 70.2	01 70.2	1 10.2	10.2	10.2		29.0	•	Revenue of \$50M from the license						
Others	48	94	47	5.2	12.2	7.0	1.9	135.2																	
Total	652	733	82	71.4	95.2	23.8	14.8	33.3	2,674	334.3	28.5														
China	ľ	Million RMB			Billi	ions of yen			Million RMB	Billions of yen															
MEROPEN®	392	464	72	6.6	9.1	2.5	1.2	37.7	863	16.8	54.1	•	China segment MEROPEN [®] increased												
Others	111	129	19	1.9	2.5	0.6	0.3	31.9	553	10.8	23.5		continuously												
Total	503	594	91	8.5	11.6	3.1	1.6	36.4	1,416	27.6	42.1		,												


FX rates: Q1FY2021 Results : 1US\$ = ¥109.5, 1RMB = ¥17.0 O1FY2022 Results : 1US\$ = ¥129.7, 1RMB = ¥19.6

Q1FY2022 Results : 1US\$ = ¥129.7, 1RMB = ¥19.6 FY2022 forecasts : 1US\$ = ¥125.0, 1RMB = ¥19.5

Sumitomo Pharma

Financial Results for Q1 FY2022 Marketing Status of ORGOVYX[®]

Obtained approx. 3,500 new patient starts in Q1 FY2022 (24% growth vs. Q4 FY2021)




- Prescribed approx. 18,000 patients since launch
- Prescribed approx. 80% of the total at Dispensing Clinics, Academic, etc.
- Secured broad payer coverage continues
 Commercial 81% of lives
 Medicare Part D 99% of lives

(includes patients on free and commercial drug, excludes patients utilizing product samples)

- 75% of patients pay less than \$60 out of pocket per month
- Gross to Net remains in the low-to-mid 40% range

Financial Results for Q1 FY2022 Marketing Status of MYFEMBREE®

Obtained approx. 2,400 new patient starts in Q1 FY2022 (71% growth vs. Q4 FY2021)



GnRH antagonists therapies for uterine fibroids in June 2022

75% of patients pay \$5 or less out of pocket per month

Sumitomo Pharma Source : Presentation of First Fiscal Quarter 2022 Earnings Conference Call of Myovant Sciences Ltd.

Financial Results for Q1 FY2022 Marketing Status of GEMTESA®

Prescribed 38,100 TRx in June 2022 and ahead of our FY2022 forecast

	GEM	TESA ®
	March 2022	June 2022
TRx Share in Beta 3	6.4%	9.3%
Monthly TRx numbers	26,145	38,100

Coverage has not expanded since March 2022. Plan to secure most of peak coverage during FY2022

	GEMI	ESA [®]
	March 2022	June 2022
All of commercial lives (Approx. 180 million)	55%	55%
All of Medicare Part D lives (Approx. 48 million)	30%	30%

Entered into an exclusive license agreement with Pierre Fabre to commercialize vibegron in Europe (July 2022)

Urovant to receive compensation of up to USD \$75 million including upfront payment, regulatory and sales milestones as well as royalties

Sumitomo Pharma

Financial Results for Q1 FY2022 Segment Information (Core Basis)

			Pharm	aceuticals Bu	siness		Other	
		Japan	North America	China	Other Regions	Subtotal	Business	Total
	Revenue (Sales to customers)	33.7	95.2	11.6	8.4	148.9	11.0	159.9
	Cost of sales	19.1	13.5	3.7	1.2	37.5	8.5	46.1
Re	Gross profit	14.6	81.7	7.9	7.2	111.4	2.5	113.8
Results		13.0	58.6	2.6	0.4	74.6	1.4	76.0
Its		1.6	23.1	5.3	6.8	36.8	1.0	37.8
ts	R&D expenses					23.8	0.6	24.4
	Core operating profit					13.0	0.4	13.4
C	Revenue (Sales to customers)	38.7	71.4	8.5	2.7	121.3	9.9	131.2
	Cost of sales	20.0	8.0	1.6	1.3	30.9	7.6	38.5
Re	Gross profit	18.7	63.4	6.9	1.4	90.5	2.3	92.7
Results		11.9	45.3	2.7	0.8	60.7	1.3	62.0
	Core segment profit	6.7	18.1	4.3	0.6	29.8	1.0	30.8
	R&D expenses					22.3	0.2	22.4
	Core operating profit					7.7	0.9	8.5
	Revenue (Sales to customers)	(5.0)	23.8	3.1	5.6	27.5	1.1	28.7
<u>Q</u>	SG&A expenses	1.1	13.3	(0.1)	(0.4)	13.9	0.2	14.1
Change	Core segment profit	(5.2)	4.9	1.1	6.2	7.0	0.0	7.0
ge	R&D expenses					1.5	0.5	2.0
	Core operating profit					5.3	(0.4)	4.9

Billions of yen

- Japan: Lower profit due to declined sales by NHI price revision and increased expenses
- North America: Profit increased since the impact of higher revenue exceeded increased expenses
- China: Profit increased mainly due to higher revenue
- Other Regions: Profit includes the revenue of \$50M from the license agreement for DSP-0187

Sumitomo Pharma



Research and Development

Sumitomo Pharma

Research and Development

Development Pipeline (as of July 29, 2022)


E Psychiatry & Neurology : Oncology : Regenerative medicine / Cell therapy : Others : Frontier business No revisions since the announcement of May 2022					
Area	Phase 1		Phase 2	Phase 3	NDA submitted
Japan	DSP-9632P (Levodopa-induced dyskinesia in Parkinson's disease) DSP-0187 (Narcolepsy)	DSP-0390 (Solid tumors) TP-3654 (Hematologic malignancies) DSP-5336 (Hematologic malignancies) guretolimod (DSP-0509) (Solid tumors)	EPI-589 (ALS/Investigator-initiated study) Allo iPS cell-derived products (Parkinson's disease/ Investigator-initiated study)	ulotaront (SEP-363856) (Schizophrenia) SEP-4199 (Bipolar I depression)	METGLUCO [®] (metformin) (New indication: infertility treatment)
U.S.	DSP-6745 (Parkinson's disease psychosis)SEP-378608 (Bipolar disorder)DSP-3905 (Neuropathic pain)SEP-378614 (To be determined)SEP-380135 (To be determined)DSP-0038 (Alzheimer's disease psychosis)DSP-3456 (Treatment resistant depression)	guretolimod (DSP-0509) (Solid tumors) TP-1287 (Solid tumors) TP-3654 (Hematologic malignancies) TP-1454 (Solid tumors) DSP-0390 (Solid tumors) DSP-5336 (Hematologic malignancies) KSP-1007 (Complicated urinary tract infections, Complicated intra-abdominal infections)	EPI-589 (Parkinson's disease/ALS) ulotaront (SEP-363856) (Parkinson's disease psychosis) dubermatinib (TP-0903) (AML/Research group- initiated study) DSP-7888 (Solid tumors) rodatristat ethyl (Pulmonary arterial hypertension) URO-902 (Overactive bladder)	ulotaront (SEP-363856) (Schizophrenia) SEP-4199 (Bipolar I depression) GEMTESA [®] (vibegron) (New indication: OAB in men with BPH)	MYFEMBREE® (relugolix) (New indication: Endometriosis) PDUFA goal date: Aug. 2022
China				LATUDA® (New indication: Bipolar I depression) ulotaront (SEP-363856) (Schizophrenia)	lefamulin (Bacterial community-acquired pneumonia)

Sumitomo Pharma

Research and Development

Product Launch Target (Frontier business) (as of July 29, 2022)

Revisions since the announcement of May 2022 are shown in red



*1 Certified medical device named "Active extension / flexion / extension rotation exercise device" (Accepted name for medical devices), plan to launch in August 2022 by Sumitomo Pharma

*2 Full-scale sales primarily by partners (Aikomi : our associated company)

*3 Sales primarily by partners (BehaVR) (Profit share 50-50 with both companies)

The project description varies with the product (device sales, solution business, royalties, etc.)



Appendix

<Contents>

- P.14 Q1 FY2022 Financial Results (Full Basis) Main Events/Targets for FY2022 P.15 R&D
- Product Launch Target P.16 R&D
- Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline P.17 R&D



Appendix (Financial Results for Q1 FY2022) Financial Results for Q1 FY2022 (Full Basis)

Billions of yen

	Q1 YTD FY2021	Q1 YTD FY2022	Cha	nge
	Results	Results	Value	%
Revenue	131.2	159.9	28.7	21.9
Cost of sales	38.5	46.1	7.6	19.7
Gross profit	92.7	113.8	21.1	22.8
SG&A expenses	62.1	77.3	15.2	24.5
R&D expenses	22.4	24.4	2.0	8.9
Other operating income and expenses	0.1	2.5	2.4	
Operating profit	8.3	14.6	6.3	75.9
Finance income and costs	(0.3)	32.0	32.3	
Profit before taxes	8.0	46.6	38.7	485.8
Income tax expenses	7.2	18.5	11.4	
Net profit	0.8	28.1	27.3	_
Net profit attributable to owners of the parent	4.8	31.1	26.3	547.8

Sumitomo Pharma

Appendix (Research and Development)

Main Events / Targets for FY2022 (as of July 29, 2022)


Completed action / target Revisions since the announcement of May 2022 are shown in red

Psychiatry & Neurology	 ulotaront : Start clinical studies for two new indications (SEP-363856) Advance Phase 3 study in the U.S. and Phase 2/3 study in Japan and China for schizophrenia SEP-4199: Advance Phase 3 studies for Bipolar I depression
Oncology	 relugolix : (Europe) Obtain approval for prostate cancer Advance early Phase studies
Regenerative medicine / Cell therapy	 Allogeneic iPS cell-derived products (AMD: age-related macular degeneration) : Start clinical study Allogeneic iPS cell-derived products (Parkinson's disease) : Start clinical study in the U.S. Start construction of manufacturing plant in the U.S (for RETHYMIC[®] and allogeneic iPS cell-derived products)
Infectious Diseases	 KSP-1007 (Antimicrobial resistance) : Complete Phase 1 study in the U.S. universal influenza vaccine, malaria vaccines : Promote joint research and development projects
Others	 relugolix : (U.S.) (Europe) Submit MAA for endometriosis
Frontier	 Launch products: (Japan) Neurorehabilitation device for hand/figures (U.S.) VR contents for mental health Generating evidence data for maximizing the value of the launched products: Digital device for relieving BPSD, etc. Promote the current themes and development of new themes
Sumitomo P	© Sumitomo Pharma Co., Ltd. All Rights Reserved. 15

Appendix (Research and Development)

Product Launch Target (as of July 29, 2022)

No revisions since the announcement of May 2022



Sumitomo Pharma

Appendix (Research and Development)

Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (as of July 29, 2022)

Region Proposed indication, etc. Partnering Cell type status (planned) Pediatric congenital Duke athymia Global Cultured thymus tissue Launched in March 2022 (U.S.) University (RETHYMIC[®]) Aim to start Allo iPS cell-derived AMD Healios clinical study (age-related macular Global retinal pigment Preparing to start clinical study (Japan) RIKEN in FY2022 degeneration) epithelium Parkinson's disease Allo iPS cell-derived **Kyoto** In progress: investigator-initiated study Aim to (Designated as a Universitv Global dopamine neural (Phase 1 / 2 study) (Japan) launch in CiRA Preparing to start clinical study (U.S.) "SAKIGAKE") progenitor FY2024 * Allo iPS cell-derived **Retinitis pigmentosa** RIKEN Global photoreceptor In progress: clinical research (3D) In progress: clinical research (Sub-Acute Keio University Allo iPS cell-derived Phase) Spinal cord injury Osaka National Global neural progenitor In progress: pre-clinical study (Chronic Hospital Phase) Auto/ Allo iPS cell-Jikei University based induced nephron Japan, **Kidney failure** In progress: pre-clinical study North America Bios progenitor cells (organ)

Revisions since the announcement of May 2022 are shown in red

* Launch schedule is based on our goal pending agreement with partners

